Investigating the role of a PRMT5 in Ewing sarcoma and its potential as a target for treatment
Professor Clare Davies and Dr Susanne Gatz explore whether PRMT5 inhibitors could be an effective and kinder treatment for Ewing sarcoma.
We have been funding expert research since 2016, aiming to ensure that every child and young person has a safe and effective treatment for their cancer, and that they can live long and happy lives post-treatment.
Professor Clare Davies and Dr Susanne Gatz explore whether PRMT5 inhibitors could be an effective and kinder treatment for Ewing sarcoma.
Professor Plevin and Dr Margaret Cunningham will investigate an enzyme that might play a role in osteosarcoma development, and see whether this could form the basis of a new type of treatment.
How the 3D shape of fusion gene genetic code affects cancer cell behaviour and whether shape-modifying medicines could mitigate these effects.
Assessing rhabdomyosarcoma risk prediction markers based on the biological conditions in the tumour, like low oxygen levels, few blood vessels, and genetics.
Looking at why ALCL sometimes relapses with a new targeted treatment, and understanding how to optimise this treatment approach.
Looking at the differences between healthy brain cells before and after treatment to uncover the mechanisms behind brain-related late effects.
Finding a way to identify patients at risk of brain related side effects from leukaemia treatment, and gathering data to inform future treatment options.
Developing a test that can measure the amount of chemotherapy-resistant leukaemia cells in patient's blood samples. This would provide the foundations for future research.
Learning more about leukaemia cells in order to design targeted treatments that can increase survivorship and quality of life.